Formulation and evaluation of a sublingual tablet containing terbutaline sulphate: Optimisation and in vivo studies;Formulación y evaluación de comprimidos sublinguales con sulfato de terbutalina: Estudios de optimización e in vivo

Ars Pharmaceutica

Volumn 46, Issue 2, 2005, Pages 139-158

  Narendra, C ^a,b   Srinath, M S ^a   Prakash, B Rao ^b  

^a Govt College of Pharmacy   (India)

^b KRUPANIDHI COLLEGE OF PHARMACY   (India)

Author keywords

Crospovidone; Factorial design; Microcrystalline cellulose; Optimisation; Sublingual tablets; Terbutaline sulphate

Indexed keywords

CROSPOVIDONE; MICROCRYSTALLINE CELLULOSE; TERBUTALINE SULFATE;

ANIMAL EXPERIMENT; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; GRANULATION TISSUE; IN VIVO STUDY; MALE; NONHUMAN; PATIENT COMPLIANCE; QUANTITATIVE ANALYSIS; TECHNIQUE;

EID: 24644473552     PISSN: 00042927     EISSN: 00042927     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Dushendra JC, Li-Lan HC, Chien YW. Characterization of captopril sublingual permeation: Determination of preferred routes and mechanisms. J Pharm Sci 2001; 90: 1868-1877.
2. Kumar S, Seth SD. Ch. 4 Respiratory system drugs: Therapy of bronchial asthma. In: Seth SD (ed). Text book of pharmacology, BI Churchil Livingstone Pvt. Ltd., London, 1999; pp 185-193.
3. Tenjarla SN, Puranajoti P, Kasina R, Mandal T. Terbutaline trasdermal delivery: Preformulation studies and limitations of in-vitro predictive parameters. J Pharm Pharmacol 1996; 48: 1138-1142.
4. Lewis GA, Mathieu D, Phan-Tan-Luu R. Pharmaceutical experimental design, Marcel Dekker, New York. 1999; pp 210-220.
5. Pharmacopoeia of India. New Delhi: Ministry of Health and Family Welfare, Government of India, Controller of Publications, 1996.
6. Kamalapurkar TS, Chudasma JJ. Spectrophotometric estimation methods of terbutaline sulphate. Indian Drugs 1983; 20: 167-168.
7. European Pharmacopoeia. Council of Europe, Stransbourg Cedex, France. Third edition, 1997; pp 127-135.
8. USP XXIV, The United States Pharmacopoeia Convention, Inc., Rockville, Maryland, 2000; pp 185-193.
9. Westerderg M, Jonsson B, Nystrom C. Physicochemical aspects of drug release. IV. The effect of carrier particle properties on the dissolution rate from order mixtures. Int J Pharm 1986; 28: 23-31.
10. Wade A, Weller PJ. Hand book of excipients, American Pharmaceutical Association and the Pharmaceutical Press, Washington, DC.
11. Bredenberg S, Nystrom C. In vitro evaluation of bioadhesion in particulate systems and possible improvement using interactive mixtures. J Pharm Pharmacol. 2003; 55: 169-177.
12. Mattson S, Nystrom C. Evaluation of critical binder properties affecting the compatibility of binary mixtures. Drug Dev Ind Pharm 2001; 27- 181-194.
13. Kornblum SS, Stoopak SB. A new tablet disintegrating agent: cross linked polyvinylpyrrolidone. J Pharm Sci 1973; 62: 43-49.
14. Reddy RK, Mutalik S, Reddy S. Once-daily sustained-release matrix tablets of nicorandil: Formulation and in vitro evaluation. AAPS PharmSciTech 2003; 4: article 61. (http://www.aapspharmscitech.org).
15. Cirunay Jesusa-Joyce N, Plaizier-Vercammen JA. Optimization of new filler/binder for direct compression using central composite design. Drug Dev Ind Pharm 1997; 23: 945-950.
16. Caramella C, Coiombo P, Conte U, Gazzaniga A, La Manna A. the role swelling in the disintegration process. Int J Pharm Technol Prod Manuf 1984; 2: 1-5.
17. Lieberman HA, Rieger MM, Banker GS. Pharmaceutical dosage forms-Disperse systems, Vol 1, Marcel Dekker, New York. 1988; pp 438-464.